AN2 Therapeutics, Inc. (ANTX)
US — Healthcare Sector
Automate Your Wheel Strategy on ANTX
With Tiblio's Option Bot, you can configure your own wheel strategy including ANTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANTX
- Rev/Share 0.0
- Book/Share 2.2816
- PB 0.5742
- Debt/Equity 0.0
- CurrentRatio 31.9565
- ROIC -0.5612
- MktCap 35892260.0
- FreeCF/Share -1.1767
- PFCF -1.011
- PE -1.0574
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4797
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
ANTX
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About AN2 Therapeutics, Inc. (ANTX)
- IPO Date 2022-03-25
- Website https://www.an2therapeutics.com
- Industry Biotechnology
- CEO Eric E. Easom
- Employees 22
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.